The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells Francesca De IuliisLudovica TaglieriSusanna Scarpa PRECLINICAL STUDIES 19 March 2016 Pages: 399 - 406
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells Bo Mi KuYeon-Hee BaeMyung-Ju Ahn PRECLINICAL STUDIES 05 April 2016 Pages: 407 - 415
Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice Bence KapuváriRózsa HegedüsGábor Mező PRECLINICAL STUDIES Open access 05 May 2016 Pages: 416 - 423
Peloruside A, a microtubule-stabilizing agent, induces aneuploidy in ovarian cancer cells Ariane ChanA. Jonathan SinghJohn H. Miller PRECLINICAL STUDIES 07 May 2016 Pages: 424 - 438
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma Shailender BhatiaAnna C. PavlickOmid Hamid PHASE I STUDIES Open access 08 April 2016 Pages: 439 - 449
A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187 Eric X. ChenDerek J. JonkerLesley Seymour PHASE I STUDIES 13 April 2016 Pages: 450 - 457
Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin Christopher C. CossAmanda JonesJames T. Dalton PHASE I STUDIES 22 April 2016 Pages: 458 - 467
Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases Michiro TakahashiKiyoshi HasegawaNorihiro Kokudo PHASE I STUDIES 07 May 2016 Pages: 468 - 473
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer Joseph KattanMarwan BachourMarwan Ghosn PHASE II STUDIES 10 May 2016 Pages: 474 - 480
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer Paul L. SwiecickiEmily BellileFrancis P. Worden PHASE II STUDIES 26 May 2016 Pages: 481 - 489
Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer Seiichiro SuzukiMasato KarayamaTakafumi Suda PHASE II STUDIES 09 June 2016 Pages: 490 - 496
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies Yaghoub SafdariVahideh AhmadzadehSafar Farajnia REVIEW 13 April 2016 Pages: 497 - 512
Why balls are not put inside the basket? A reflection on testicular cancer clinical trial design Hampig Raphael KourieFouad Aoun SHORT REPORT 10 March 2016 Pages: 513 - 514
Peptide aptamer identified by molecular docking targeting translationally controlled tumor protein in leukemia cells Onat KadiogluThomas Efferth SHORT REPORT 14 March 2016 Pages: 515 - 521
The imidazoline compound RX871024 promotes insulinoma cell death independent of AMP-activated protein kinase inhibition Irina I. ZaitsevaSergei V. ZaitsevPer-Olof Berggren SHORT REPORT 25 May 2016 Pages: 522 - 529